8-K: Perrigo Reports Q1 2026 Results, Maintains Full-Year Outlook

Perrigo Company plc announced first quarter 2026 financial results, showing progress on its ThreeS plan despite category headwinds, and reaffirmed its full-year guidance.

Summary

• Perrigo Company plc reported first quarter 2026 financial results from continuing operations, with net sales of $969 million (All In) and $842 million (Core).
• The company experienced a 7.2% decrease in All In net sales and an 8.3% decrease in Core net sales year-over-year.
• Adjusted Gross Margin decreased by 340 basis points (All In) to 37.6% and 160 basis points (Core) to 39.2%.
• Adjusted Operating Margin decreased by 240 basis points (All In) to 11.6% and 110 basis points (Core) to 12.8%.
• Reported diluted EPS was $(2.81), primarily due to a $330.8 million goodwill impairment charge.
• Core adjusted diluted EPS decreased 20.0% to $0.40, and All In adjusted diluted EPS decreased 28.3% to $0.43.
• The company completed the divestiture of its Dermacosmetics business for up to $332.6 million, with upfront proceeds of $305.6 million to support debt reduction.
• Perrigo maintained its full-year 2026 outlook, expecting second-half improvement driven by growth initiatives and the Operational Enhancement Program.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment score due to the reported decline in net sales, reduced earnings per share, and significant goodwill impairment charge, despite the reaffirmation of the full-year outlook and positive performance in specific segments.

Positives

• Specialty Care segment achieved net sales growth of 4.0% and segment operating income growth of 31.4%, driven by momentum in Compeed, Opill, and ellaOne brands.
• Perrigo U.S. store brand OTC volume share increased by 100 basis points.
• The company completed the divestiture of its Dermacosmetics business, with upfront proceeds of $305.6 million to support debt reduction.
• The company reaffirmed its full-year 2026 outlook, anticipating second-half improvement.
• A recovery of approximately $21 million for previously paid tariffs was recognized.
• Favorable currency translation provided a positive impact on net sales and operating income in certain segments.

Negatives

• All In reported net sales decreased by 7.2% to $969 million.
• Core net sales decreased by 8.3% to $842 million, with Core organic net sales down 11.0%.
• Reported gross margin decreased by 400 basis points to 33.6%.
• Reported operating margin was a loss of (38.4)% compared to 4.5% in the prior year, largely due to a $330.8 million goodwill impairment charge.
• Core adjusted diluted EPS declined 20.0% to $0.40.
• All In adjusted diluted EPS declined 28.3% to $0.43.
• First quarter cash flow from operating activities was an outflow of $114 million, a decrease of $49 million from the prior year.
• Self Care segment net sales decreased 11.5% and segment operating income decreased 39.3%.

Risks

• Potential impacts related to geopolitical developments in the Middle East are being monitored.
• Retailer inventory destocking is creating a net sales headwind.
• Lower seasonal incidence of cough and cold versus the prior year impacted sales.
• Supply chain impacts, including those caused or exacerbated by armed conflict, trade and economic sanctions, and disease.
• General economic, credit, and market conditions.
• Increased or new tariffs and changes in global trade relations.
• Uncertainty regarding the ability to obtain and maintain regulatory approvals.
• Potential costs and reputational impact of product recalls or sales halts.

Future Outlook

Perrigo reaffirms its full-year 2026 outlook, expecting second-half results to benefit from growth initiatives, the Operational Enhancement Program, and lapping prior-year category consumption and manufacturing volume headwinds. The company anticipates an unfavorable All In EPS impact of approximately $0.60 in 2026 due to prior-year manufacturing volume headwinds, with approximately $0.26 of that impact occurring in the first quarter. The company expects net sales growth of -5.5% to -1.5% (All In Ex Infant Formula Ex Divestitures), adjusted gross margin of 36.5% to 37.5%, adjusted operating margin of 12.5% to 13.5%, and adjusted EPS of $2.00 to $2.30.

Management Comments

• "Our first quarter results reflect tangible progress as we continue to transform Perrigo into a more focused, disciplined, and consistent business."
• "Despite a challenging operating environment, we are advancing a clear plan to address the factors within our control."
• "Our ThreeS plan and shift to a category-led operating model are strengthening execution and accountability, and the momentum we are seeing in areas such as U.S. Store Brand and Womens Health are encouraging."
• "We also continue to simplify and streamline the organization through disciplined portfolio actions, including the sale of our Dermacosmetics business, with proceeds expected to be used to support debt reduction."
• "We are maintaining our fullyear guidance, supported by clear, quantifiable factors expected to drive improvement in the second half of the year."
• "We recognize that the environment is dynamic, and we are monitoring potential impacts related to geopolitical developments in the Middle East and retailer inventory destocking."
• "Against this backdrop, we are well-positioned to deliver on our 2026 outlook while building a foundation for long-term growth."

Industry Context

StockSavvy.ai notes that Perrigo's Q1 2026 results reflect the broader challenges faced by consumer self-care companies, including lower seasonal demand, retailer inventory adjustments, and ongoing geopolitical uncertainties. The company's strategic focus on its 'ThreeS' plan and category-led model aims to counter these headwinds, with positive traction observed in specific segments like Women's Health, indicating a potential for market share gains in a competitive landscape.

Comparison to Industry Standards

• The decline in net sales and margins for Perrigo's Self Care segment is consistent with broader trends in the consumer staples sector, where companies are navigating reduced consumer spending and inventory destocking by retailers.
• The Specialty Care segment's growth, particularly in Women's Health brands like Opill and ellaOne, highlights a successful strategy in niche markets, contrasting with the more challenging performance in broader OTC categories.
• The company's focus on debt reduction through divestitures aligns with industry practices aimed at strengthening balance sheets and improving financial flexibility in uncertain economic times.

Legal Proceedings

• Unusual litigation is mentioned as an item excluded from non-GAAP financial measures.

Stakeholder Impact

• Shareholders: Potential impact from reduced EPS and ongoing strategic transformation, balanced by reaffirmed full-year guidance and debt reduction efforts.
• Creditors: Positive impact from the use of divestiture proceeds to support debt reduction.
• Employees: Potential impact from restructuring charges and ongoing strategic initiatives.
• Customers: Continued focus on product innovation and market share gains in key categories.

Next Steps

• Continue execution of the ThreeS plan and category-led operating model.
• Drive second-half improvement through growth initiatives and the Operational Enhancement Program.
• Monitor potential impacts from geopolitical developments in the Middle East.
• Manage retailer inventory levels and stabilize consumption trends.
• Utilize proceeds from the Dermacosmetics divestiture to support debt reduction.

Key Dates

Recommendation

The company's Q1 results show significant headwinds with declining sales and earnings, exacerbated by a large goodwill impairment. While management is taking steps to address these issues and has reaffirmed its full-year outlook, the extent of the current challenges and the reliance on second-half improvements warrant a cautious 'hold' rating until more concrete evidence of recovery is presented.

Keywords

Perrigo, 8-K, Q1 2026, Financial Results, Consumer Self-Care, Specialty Care, Divestiture, Outlook